Search
Sutimlimab
go.drugbank.com/drugs/DB14996ApprovedInvestigational[L40114,A245144] Sutimlimab was also approved by the European Commission in November 2022.[L44116] … [A245144] It received FDA approval in February 2022, under the brand name Enjamyo (sutimlimab-jome), becoming the first approved therapy for patients with CAD.
Linseed oil
go.drugbank.com/drugs/DB11357InvestigationalLinseed oil is particularly susceptible to polymerization reactions upon exposure to oxygen in air due to a high content of di- and triunsaturated esters. … Linseed oil is a rich source of α-Linolenic acid extracted from the dried, ripened seeds of the flax plant *Linum usitatissimum*.
Amsacrine
go.drugbank.com/drugs/DB00276ApprovedInvestigationalWithdrawnAminoacridine derivative that is a potent intercalating antineoplastic agent.
Categories: Compounds used in a research, industrial, or household settingInternational brands: AMSA P-DNNZ-2591
go.drugbank.com/drugs/DB15601InvestigationalIt was granted Orphan Drug Designation by the FDA in October 2019[L11103] and was granted a patent by the European Patent Office in December 2019. … NNZ-2591 (cyclo-L-glycyl-L-2-allylproline)[A189390] is an investigational synthetic analog of cyclic glycine-proline (cGP), a breakdown product of human insulin-like growth factor 1 (IGF-1), that has been
Synonyms: Pyrrolo(1,2-a)pyrazine-1,4-dione, hexahydro-8a-(2-propenyl)-, (8aR)-Nuvaxovid
go.drugbank.com/drugs/DB15810ApprovedInvestigational(Fractions A and C from _Quillaja saponaria_ extract). … Nuvaxovid (NVX-CoV2373) contains a recombinant mutant S protein that is codon-optimized for baculovirus-mediated expression in Sf9 cells derived from _Spodoptera frugiperda_ together with a Matrix-M adjuvant
Avalglucosidase alfa
go.drugbank.com/drugs/DB16099ApprovedInvestigationalAvalglucosidase alfa, or NeoGAA, is a drug for enzyme replacement therapy specifically designed for Pompe disease, a rare inherited neuromuscular disorder caused by the deficiency of the alpha-glucosidase … [A232955] Avalglucosidase alfa is a recombinant form of GAA that restores deficient enzyme levels.
Fruquintinib
go.drugbank.com/drugs/DB11679ApprovedInvestigationalThe first approach can be exemplified by [bevacizumab], a VEGF-A trap antibody. … Therefore, the advent of fruquintinib, a new generation of VEGFR inhibitors with a high kinome selectivity, demonstrated the feasibility of the small-molecule inhibitor approach.
Desmopressin
go.drugbank.com/drugs/DB00035ApprovedInvestigationalDesmopressin, also known as 1-deamino-8-D-arginine vasopressin (DDAVP), is a synthetic analogue of the natural posterior pituitary hormone arginine vasopressin (AVP) [A275458, L56105]. … On January 15, 2026, the FDA approved a new low-dose sublingual film formulation specifically for the treatment of nocturia in patients at high risk for fluid overload, utilizing a specialized delivery
Synonyms: 1 deamino 8 D argininevasopressin, 1-deamino-8-D-arginine vasopressinUmbilical Cord Blood Hematopoietic Stem Cells
go.drugbank.com/drugs/DB15723InvestigationalBecause HUCBC are largely immature, do not express class II HLA antigens, and do not produce as many cytokines and immunoglobulins as adult lymphocytes, transplantation with these cells means low levels … UCB contains a large source of hematopoietic stem cells (HSCs) that are capable of self-renewal, have increased sensitivity to various factors, and are able to generate erythroid and myeloid progenitor
Nedaplatin
go.drugbank.com/drugs/DB13145ApprovedInvestigationalNedaplatin is a second generation platinum analog [A20300]. It is less nephrotoxic than [DB00515] but has proven equally effective. It was approved for use in Japan in 1995.
Categories: Drugs that are Mainly Renally Excreted with a Narrow Therapeutic Index